TY - JOUR
T1 - Inpatient epidemiology and economic burden of granulomatosis with polyangiitis
T2 - a 10-year study of the national inpatient sample
AU - Ungprasert, Patompong
AU - Koster, Matthew J.
AU - Cheungpasitporn, Wisit
AU - Wijarnpreecha, Karn
AU - Thongprayoon, Charat
AU - Kroner, Paul T.
N1 - Publisher Copyright:
© 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Objective: To characterize inpatient epidemiology and economic burden of granulomatosis with polyangiitis (GPA). Methods: Patients with GPA were identified from the Nationwide Inpatient Sample (NIS), the largest inpatient database in the USA consisting of over 4000 non-federal acute care hospitals, using the ICD-9 CM code. A cohort of comparators without GPA was also constructed from the same database. Data on demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges were extracted. All analysed data were extracted from the database for the years 2005-2014. Results: The inpatient prevalence of GPA was 32.6 cases per 100 000 admissions. GPA itself (38.3%), pneumonia (13.7%) and sepsis (8.4%) were the most common reasons for admission. After adjusting for potential confounders, the all-cause mortality adjusted odds ratio (aOR) of patients with GPA was significantly higher than that of patients without GPA (aOR 1.20; 95% CI: 1.41, 1.61). This was also true for several morbidities, including acute kidney injury, multi-organ failure, shock and need for intensive care unit admission. Hospitalizations of patients with GPA were associated with higher cost as demonstrated by an adjusted additional mean of $5125 (95% CI: $4719, $5531) for total hospital cost and an adjusted additional mean of $16 841 (95% CI: $15 280, $18 403) for total hospitalization charges when compared with patients without GPA. Conclusion: Inpatient prevalence of GPA was higher than what would be expected from prevalence in the general population. Hospitalizations of patients with GPA were associated with higher morbidity, mortality and cost.
AB - Objective: To characterize inpatient epidemiology and economic burden of granulomatosis with polyangiitis (GPA). Methods: Patients with GPA were identified from the Nationwide Inpatient Sample (NIS), the largest inpatient database in the USA consisting of over 4000 non-federal acute care hospitals, using the ICD-9 CM code. A cohort of comparators without GPA was also constructed from the same database. Data on demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges were extracted. All analysed data were extracted from the database for the years 2005-2014. Results: The inpatient prevalence of GPA was 32.6 cases per 100 000 admissions. GPA itself (38.3%), pneumonia (13.7%) and sepsis (8.4%) were the most common reasons for admission. After adjusting for potential confounders, the all-cause mortality adjusted odds ratio (aOR) of patients with GPA was significantly higher than that of patients without GPA (aOR 1.20; 95% CI: 1.41, 1.61). This was also true for several morbidities, including acute kidney injury, multi-organ failure, shock and need for intensive care unit admission. Hospitalizations of patients with GPA were associated with higher cost as demonstrated by an adjusted additional mean of $5125 (95% CI: $4719, $5531) for total hospital cost and an adjusted additional mean of $16 841 (95% CI: $15 280, $18 403) for total hospitalization charges when compared with patients without GPA. Conclusion: Inpatient prevalence of GPA was higher than what would be expected from prevalence in the general population. Hospitalizations of patients with GPA were associated with higher morbidity, mortality and cost.
KW - ANCA associated vasculitis
KW - economic burden
KW - epidemiology
KW - granulomatosis with polyangiitis
KW - hospitalization
UR - http://www.scopus.com/inward/record.url?scp=85087984696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087984696&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keaa069
DO - 10.1093/rheumatology/keaa069
M3 - Article
C2 - 32129858
AN - SCOPUS:85087984696
SN - 1462-0324
VL - 59
SP - 3685
EP - 3689
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 12
ER -